[1]王雨涛,周济,杨冬,等.TRIM29基因在胶质瘤中的表达及其对胶质母细胞瘤细胞U-87 MG增殖与迁移的影响[J].第三军医大学学报,2018,40(11):959-965.
 WANG Yutao,ZHOU Ji,YANG Dong,et al.Expression of TRIM29 in gliomas and its effect on proliferation and migration of glioblastoma U-87 MG cells[J].J Third Mil Med Univ,2018,40(11):959-965.
点击复制

TRIM29基因在胶质瘤中的表达及其对胶质母细胞瘤细胞U-87 MG增殖与迁移的影响(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第11期
页码:
959-965
栏目:
基础医学
出版日期:
2018-06-15

文章信息/Info

Title:
Expression of TRIM29 in gliomas and its effect on proliferation and migration of glioblastoma U-87 MG cells
作者:
王雨涛周济杨冬张云东
陆军军医大学(第三军医大学)第三附属医院(野战外科研究所)神经外科;解放军火箭军总医院神经外科;重庆医科大学第三附属医院神经疾病中心
Author(s):
WANG Yutao ZHOU Ji YANG Dong ZHANG Yundong

Department of Neurosurgery, Institute of Surgery Research, Third Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400042; Department of Neurosurgery, General Hospital of PLA Rocket Force, Beijing, 100088; 3Department of Neurosurgery, the Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China

关键词:
TRIM29胶质母细胞瘤增殖迁移
Keywords:
TRIM29 glioblastoma proliferation migration
分类号:
R394.2; R730.23; R730.264
文献标志码:
A
摘要:

目的    观察TRIM29基因在胶质瘤组织中的表达及其与临床病理特征的关系,探讨其对胶质母细胞瘤细胞U-87 MG增殖与迁移的影响以及可能的作用机制。方法    采用免疫组织化学法检测56例胶质瘤组织和正常脑组织中TRIM29蛋白的表达,分析胶质瘤组织中TRIM29蛋白表达与临床病理特征的关系。Western blot 检测胶质母细胞瘤组织、癌旁组织及正常组织中TRIM29蛋白的表达,同时检测其在不同胶质瘤细胞株(A172、LN-229、U-87 MG、U-118 MG)中的表达。利用RNA干扰技术处理高表达TRIM29的胶质母细胞瘤细胞U-87 MG,并分为空白对照组、shScramble组(阴性对照组)及shTRIM29组(实验组)。采用MTT实验、克隆形成实验和Transwell实验分别检测敲低TRIM29对胶质母细胞瘤细胞U-87 MG增殖和迁移能力的影响。进一步通过裸鼠成瘤实验检测敲低TRIM29在体内对胶质母细胞瘤细胞U-87 MG增殖的影响。采用Western blot 检测TRIM29敲低后AKT通路蛋白的变化。结果    TRIM29在胶质瘤组织中较正常脑组织表达增加,且与患者WHO分级呈正相关(r=0.535,P<0.05)。Western blot检测结果显示,与正常脑组织和癌旁组织相比,胶质母细胞瘤组织中TRIM29蛋白的表达明显上调(P<0.05)。TRIM29在胶质瘤细胞A172、LN-229、U-87 MG、U-118 MG中蛋白的表达分别为(0.27±0.02)、(0.69±0.04)、(1.24±0.08)、(0.82±0.06)。RNA干扰处理后,shTRIM29组U87 MG细胞TRIM29蛋白的表达量为(0.27±0.04),明显低于空白对照组和shScramble组[(1.64±0.05)、(1.51±0.05),P<0.05]。同时,与空白对照组和shScramble组相比,shTRIM29组U-87 MG细胞的增殖、迁移能力明显下降(P<0.05)。在胶质母细胞瘤细胞U-87 MG中敲低TRIM29后,p-AKT蛋白表达明显降低(P<0.05)。结论        TRIM29在胶质瘤中高表达,与肿瘤的恶性程度呈正相关,可能通过AKT信号通路促进细胞的增殖及迁移。

Abstract:

Objective    To observe the expression of TRIM29 in glioma tissues and its relationship with clinicopathological features, and to determine its effect on the proliferation and migration of glioblastoma U-87 MG cells and investigate its possible mechanism. Methods    Immunohistochemical assay was used to detect the expression of TRIM29 protein in 56 samples of glioma tissues and normal brain tissues, and the relationship between TRIM29 protein level and clinicopathological features was analyzed. Western blotting was used to detect the expression of TRIM29 protein in the glioblastoma tissues, paracancerous tissues and normal tissues, and in different glioma cell lines (A172, LN-229, U-87 MG and U-118 MG). RNA interference technique was used to treat the U-87 MG cells (with high expression of TRIM29), and then the cells were divided into 3 groups: blank control group, shScramble group and shTRIM29 group. Subsequently, MTT assay, colony formation assay and Transwell chamber test were used respectively for the effects of TRIM29 knockdown on the proliferation and migration of the U-87 MG cells. The effect was further studied through nude mouse tumorigenesis assay. Finally, Western blotting was used to detect the changes of AKT pathway proteins after the knockdown of TRIM29. Results    The expression of TRIM29 in glioma tissue was higher than that in normal brain tissue, and positively correlated with the WHO grade (r=0.535, P<0.05). Western blotting showed that the expression of TRIM29 protein was significantly up-regulated in glioblastoma tissues when compared with normal brain tissues and adjacent normal tissues (P<0.05). The protein level of TRIM29 was 0.27±0.02, 0.69±0.04, 1.24±0.08 and 0.82±0.06, respectively in glioma A172, LN-229, U-87 MG and U-118 MG cells. In the U-87 MG cells after RNA interference, the protein expression of TRIM29 was 0.27±0.04, significantly lower than that of the blank control group (1.64±0.05, P<0.05) and that of shScramble group (1.51±0.05, P<0.05). The proliferation and migration were significantly decreased of in the TRIM29 knockdown U-87 MG cells than the blank control and negative control groups (P<0.05). In addition, the knockdown of TRIM29 also decreased the p-AKT protein level (P<0.05). Conclusion    TRIM29 is highly expressed in gliomas and positively correlated with tumor malignancy, and it may promote the proliferation and migration of the cells through the AKT signaling pathway.

参考文献/References:

[1]RIDDICK G, FINE H A. Integration and analysis of genomescale data from gliomas[J]. Nat Rev Neurol, 2011, 7(8): 439-450. DOI:10.1038/nrneurol.2011.100.
[2]MEYER M A. Malignant gliomas in adults[J]. N Engl J Med, 2008, 359(17): 1850; author reply 1850. DOI:10.1056/NEJMc086380.
[3]KIM E, KIM M, WOO D H, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stemlike cells[J]. Cancer Cell, 2013, 23(6): 839-852. DOI:10.1016/j.ccr.2013.04.008.
[4]DAGOGOJACK I, SHAW A T. Tumour heterogeneity and resistance to cancer therapies[J]. Nat Rev Clin Oncol, 2018, 15(2): 81-94. DOI:10.1038/nrclinonc.2017.166.
[5]KIMURA T, JIA J, KUMAR S, et al. Dedicated SNAREs and specialized TRIM cargo receptors mediate secretory autophagy[J]. EMBO J, 2017, 36(1): 42-60. DOI:10.15252/embj.201695081.
[6]SATO T, TAKAHASHI H, HATAKEYAMA S, et al. The TRIMFLMN protein TRIM45 directly interacts with RACK1 and negatively regulates PKCmediated signaling pathway[J]. Oncogene, 2015, 34(10): 1280-1291. DOI:10.1038/onc.2014.68.
[7]UCHIL P D, HINZ A, SIEGEL S, et al. TRIM proteinmediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity[J]. J Virol, 2013, 87(1): 257-272. DOI:10.1128/JVI.0180412.
[8]LOEDIGE I, GAIDATZIS D, SACK R, et al. The mammalian TRIMNHL protein TRIM71/LIN41 is a repressor of mRNA function[J]. Nucleic Acids Res, 2013, 41(1): 518-532. DOI:10.1093/nar/gks1032.
[9]MANDELL M A, KIMURA T, JAIN A, et al. TRIM proteins regulate autophagy: TRIM5 is a selective autophagy receptor mediating HIV1 restriction[J]. Autophagy, 2014, 10(12): 2387-2388. DOI:10.4161/15548627.2014.984278.
[10]KOSAKA Y, INOUE H, OHMACHI T, et al. Tripartite motifcontaining 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer[J]. Ann Surg Oncol, 2007, 14(9): 2543-2549. DOI:10.1245/s1043400794611.
[11]KANNO Y, WATANABE M, KIMURA T, et al. TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer[J]. Acta Histochem, 2014, 116(5): 708-712. DOI:10.1016/j.acthis.2013.12.009.
[12]JIANG T, TANG H M, LU S, et al. Upregulation of tripartite motifcontaining 29 promotes cancer cell proliferation and predicts poor survival in colorectal cancer[J]. Med Oncol, 2013, 30(4): 715. DOI:10.1007/s1203201307154.
[13]TANG Z P, DONG Q Z, CUI Q Z, et al. Ataxiatelangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NFκB pathway[J]. PLoS ONE, 2013, 8(6): e63676. DOI:10.1371/journal.pone.0063676.
[14]LAI W, ZHAO J, ZHANG C, et al. Upregulated ataxiatelangiectasia group D complementing gene correlates with poor prognosis in patients with esophageal squamous cell carcinoma[J]. Dis Esophagus, 2013, 26(8): 817-822. DOI:10.1111/j.14422050.2012.01400.x.
[15]AI L, KIM W J, ALPAY M, et al. TRIM29 suppresses TWIST1 and invasive breast cancer behavior[J]. Cancer Res, 2014,74(17):4875-4887. DOI:10.1158/00085472.CAN133579.
[16]STEGEMAN H, SPAN P N, KAANDERS J H, et al. Improving chemoradiation efficacy by PI3K/AKT inhibition[J]. Cancer Treat Rev, 2014, 40(10): 1182-1191. DOI:10.1016/j.ctrv.2014.09.005.

相似文献/References:

[1]徐高峰,王茂德,谢万福,等.沉默缺氧诱导因子对人胶质瘤SHG44细胞糖酵解及细胞增殖的影响[J].第三军医大学学报,2011,33(20):2148.
 Xu Gaofeng,Wang Maode,Xie Wanfu,et al.Reversal of glycolytic phenotype by HIF-1α siRNA inhibits SHG44 cell growth in vitro[J].J Third Mil Med Univ,2011,33(11):2148.
[2]张伟国.脑胶质母细胞瘤肿瘤血管及其MRI研究[J].第三军医大学学报,2013,35(24 ):2603.
 Zhang Weiguo.Glioblastoma neovascularization and MRI evaluation[J].J Third Mil Med Univ,2013,35(11):2603.

更新日期/Last Update: 2018-06-13